Meiji Pharma launches two Santen ophthalmic products in Indonesia
Category: #health  By Paroma Bhattacharya  Date: 2019-08-07
  • share
  • Twitter
  • Facebook
  • LinkedIn

Meiji Pharma launches two Santen ophthalmic products in Indonesia

Reports confirm that Meiji Seika Pharma Co., Ltd. (Meiji), a Japanese company, has recently announced the launch of two products from Santen Pharmaceutical Co. (Santen) in Indonesia, which is based on a working business agreement that Meiji commenced in November of 2018 with Santen.

Sources close to the matter informed that on the basis of the working business agreement with Santen, these two products will be commercialized in Indonesia by affiliated subsidiary of Meiji, PT. Meiji Indonesian Pharmaceutical Industries (PT. Meiji). PT. Meiji has set up a new team for marketing specializing in ophthalmic treatments, and Santen will reinforce their overall marketing activities.

Apparently, Santen and PT. Meiji work mutually to expand their market share in Indonesia for ophthalmic products. Through the marketing of ophthalmic treatments in the country, Santen and Meiji are greatly contributing towards the health of the people across ASEAN countries.

Sources further mentioned that in 2018, Santen Inc., a global company focused entirely on ophthalmology, had unveiled the expansion of its R&D leadership team through addition of two new executives namely and Peter Sallstig, MD, MBA, appointed as Senior Vice President of Global Product Development and Reza M. Haque, MD, PhD, chosen as Senior Vice President of Global Research and Development Strategy.

Seemingly, Dr. Haque was to lead the global research and development strategy for all the fields of ophthalmology including retina, glaucoma, cornea, and external diseases. On the other hand, Dr. Sallstig was responsible for the execution, design, and strategy of clinical ophthalmology programs through all sessions of development, post-marketing, and regulatory submissions.

Head and Chief Scientific Officer of Global Research and Development, Naveed Shams, MD, PhD, had said at the time that bolstering the global research and development leadership team with Peter and Reza was vital for Santen as the company looked to advance its innovative ophthalmic pipeline.

                                                                   

Source Credits: https://finance.yahoo.com/news/meiji-seika-pharma-launch-two-010000836.html



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Exicure reveals positive data from XCUR17 clinical trial for Psoriasis
Exicure reveals positive data from XCUR17 clinical trial for Psoriasis
By Paroma Bhattacharya

Clinical trials play a vital role in developing new treatments that could immensely improve a person’s living. Today, researchers and pharmaceutical company are working hard for making breakthroughs in psoriasis ...

Principia Biopharma reveals data from Phase 1/2 trial targeting ITP
Principia Biopharma reveals data from Phase 1/2 trial targeting ITP
By Paroma Bhattacharya

Immune thrombocytopenia (ITP) is a type of blood abnormality that creates a shortage of blood cell fragments known as platelets required for normal blood clotting. While children with ITP get cured without treatme...

Indian social commerce startup Mall91 raises $7.5M in Series A round
Indian social commerce startup Mall91 raises $7.5M in Series A round
By Paroma Bhattacharya

  • Mall91 reportedly plans on using the acquired funds for product development, boosting hiring and driving supply chain efforts, and realizing its global expansion ambitions.